TOPICAL REGIONAL NEURO-AFFECTIVE THERAPY IN MAMMALS WITH CANNABINOIDS
A method of treating a disease state or condition in mammals other than humans via topical brainstem afferent stimulation therapy via the administration of a cannabinoid drug(s) to the back of the neck region and/or spine to provide regional neuro-affective therapy is disclosed. In certain preferred embodiments, the cannabinoid drug(s) are not psychoactive or substantially not psychoactive. In certain embodiments, the cannabinoid drug(s) are incorporated into a pharmaceutically acceptable topical carrier, e.g., a cream or mousse. In certain preferred embodiments, the cannabinoid drug(s) comprises cannabidiol.
1 . A method of treating a disease state or condition in a mammal other than a human with a cannabinoid drug(s) comprising administering a cannabinoid drug(s) in a therapeutically effective amount to treat the disease state or condition to the back of the neck region to provide regional neuro-affective therapy.
2 . The method of claim 1 , wherein the administration is topical and is on one or more regions in an area extending from (behind) one ear to the other ear of the mammal and from the back of the head to below the neck.
3 . The method of claim 1 , wherein the cannabinoid drug(s) is further administered to an area along the spine of the mammal.
4 . The method of claim 1 , wherein the cannabinoid drug(s) is administered in a topical pharmaceutical formulation in a unit dose containing a therapeutically effective amount of the cannabinoid drug(s).
5 . The method of claim 4 , wherein the cannabinoid drug(s) is administered in a topical mousse formulation.
6 . The method of claim 1 , wherein the mammal is a canine.
7 . The method of claim 1 , wherein the cannabinoid drug(s) comprise a mixture of pharmaceutically acceptable cannabinoids, such that the mixture provides substantially no psychoactive effect or no psychoactive effect.
8 . The method of claim 1 , wherein the cannabinoid drug(s) comprises at least about 80% cannabidiol.
9 . The method of claim 4 , wherein the topical pharmaceutical formulation comprises a pharmaceutically acceptable aqueous based carrier.
10 . The method of claim 5 , wherein the cannabinoid drug(s) in the pharmaceutical formulation comprises at least about 80% cannabidiol.
11 . The method of claim 10 , wherein the topical pharmaceutical formulation further comprises an effective amount of a pharmaceutically acceptable penetration enhancer.
12 . The method of claim 11 , wherein the penetration enhancer is selected from the group consisting of isostearic acid, octanoic acid, oleic acid, oleyl alcohol, lauryl alcohol, ethyl oleate, isopropyl myristate, butyl stearate, methyl laurate, diisopropyl adipate, glyceryl monolaurate, tetrahydrofurfuryl alcohol polyethylene glycol ether, polyethylene glycol, propylene glycol, 2-(2-ethoxyethoxy)ethanol, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, alkylaryl ethers of polyethylene oxide, polyethylene oxide monomethyl ethers, polyethylene oxide dimethyl ethers, dimethyl sulfoxide, glycerol, ethyl acetate, acetoacetic ester, N-alkylpyrrolidone, terpenes, and mixtures of any of the foregoing.
13 . The method of claim 1 , wherein the cannabinoid drug(s) comprises cannabidiol.
14 . The method of claim 10 , wherein the aqueous based pharmaceutically acceptable carrier comprises Ethoxydiglycol, Water (Aqua), Glycerin, C 12-15 Alkyl Benzoate, Glyceryl Stearate, Dimethicone, Cetearyl Alcohol, Cetearyl Glucoside, Polyacrylamide, Cetyl Alcohol, Magnesium Aluminum Silicate, Xanthan Gum, Aloe Vera (Aloe Barbadensis), Tocopheryl Acetate (Vitamin E Acetate), Prunus Amygadalus Amara (Bitter Almond) Kernel Oil, Vitis Vinifera (Grape) Seed Extract, Triticum Vulgare (Wheat) Germ Oil, Retinyl Palmitate (Vitamin A Palmitate), Ascorbyl Palmitate (Vitamin C Palmitate), Pro-Lipo Multi-emulsion Liposomic System, Tetrasodium EDTA, Phenoxyethanol, and Sodium Hydroxymethylglycinate.
15 . The method of claim 8 , wherein cannabidiol is CBD—oil.
16 . The method of claim 8 wherein cannabidiol is a purified crystalline CBD.
17 . The method of claim 4 , wherein the topical pharmaceutical formulation comprises liposomes.
18 . The method of claim 4 , wherein the unit dose comprises from about 3 mg to about 100 mg cannabidiol.
19 . The method of claim 1 , further comprising formulating the cannabinoid drug(s) in a pharmaceutically acceptable topical aqueous-based carrier, and applying a sufficient amount to the back of the neck region of the human patient such that the onset of a therapeutic effect occurs in less than about 30 minutes.
20 . The method of claim 7 , wherein the cannabinoid drug mixture concentrate includes from about 0 to about 3% tetrahydrocannabinol, from about 0 to about 1% tetrahydrocannabinolic acid, from about 20 to about 50% cannabidiol, from about 0 to about 1% cannabidiolic acid, and from about 0 to about 1% cannabinol, for a total active cannabinoid level from about 20% to about 50%.
21 . The method of claim 20 , wherein the cannabinoid drug(s) in the topical pharmaceutical formulation are at a concentration from about 0.75% to about 5%, by weight.
22 . The method of claim 4 , wherein the unit dose of the cannabinoid drug(s) includes from about 1 mg to about 200 mg cannabinoid drug(s) and the cannabinoid drug(s) comprise at least 80% cannabidiol.
23 . The method of claim 1 , wherein the disease state or condition is selected from the group consisting of lameness and gait issues; elbow dysplasia; hip dysplasia; back and hind leg problems; arthritis; seizures; encephalopathy, including lethargy, focus/attentional problems, and cognitive issues: spasticity; epilepsy; cancer; weakness; pain; numbness; anxiety and other mood disorders; hypertension; tremors; peripheral neuropathy; bowel and bladder control issues; inactivity; poor appetite; tumors (e.g., pituitary tumors); Cushing's disease; aggressive behavior; pruritis; dermatitis; vomiting; lethargy; dystonia; and personality change.